SynthesisCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2026
Indobufen Dual Antiplatelet Therapy (DAPT) Versus Aspirin Dual Antiplatelet Therapy (DAPT) After Percutaneous Coronary Intervention (PCI): A Systematic Review and Meta-Analysis.
Synthesis in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Indobufen Dual Antiplatelet Therapy (DAPT) Versus Aspirin Dual Antiplatelet Therapy (DAPT) After Percutaneous Coronary Intervention (PCI): A Systematic Review and Meta-Analysis.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDual antiplatelet therapy (DAPT), which combines aspirin with a P2Y12 receptor inhibitor, is considered the standard of care for patients who have had percutaneous coronary intervention (PCI). This study aimed to compare indobufen-based (DAPT) to aspirin-based (DAPT) after PCI.
methodsThis systematic review and meta-analysis analyzed randomized controlled trials (RCTs) and propensity-matched cohort studies comparing indobufen (DAPT) to standard aspirin (DAPT) after PCI. We searched four databases: PubMed, Scopus, Web of Science, and Cochrane through January 2025 and updated the search in September 2025. Dichotomous data were pooled as odds ratios with 95% CIs.
resultsOur search identified 403 records; only five studies were included in the analysis. Comparing major adverse cardiac and cerebrovascular events (MACCE) between the indobufen and aspirin groups, no difference was observed (OR 1.12, 95% CI: 0.87-1.46; p = 0.38). Bleeding BARC types 2, 3, 5 were compared between the two groups, showing fewer bleeding events in the indobufen group than in the aspirin group (OR: 0.47, 95% CI: 0.24-0.95; p = 0.03).
conclusionIndobufen-based (DAPT) had a lower incidence of bleeding than aspirin-based (DAPT), with no difference between the two groups for MACCE, myocardial infarction, ischemic stroke, cardiovascular death, repeat vascularization, or stent thrombosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.